OraSure (OSUR) 10-K 3 Mar 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Feb. 24, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity File Number	001-16537
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
Entity Public Float			$ 197,743,692
Entity Common Stock, Shares Outstanding		73,244,807
Auditor Name	KPMG LLP
Auditor Location	Philadelphia, PA
Auditor Firm ID	185
Documents Incorporated by Reference	Documents Incorporated by Reference: Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant's Definitive Proxy Statement for its 2023 Annual Meeting of Shareholders, or will be included in an amendment hereto, to be filed not later than 120 days after the close of the fiscal year ended December 31, 2022. Except with respect to information specifically incorporated by reference in the Annual Report on Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part hereof.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 83,980	$ 116,762
Short-term investments	26,867	36,279
Accounts receivable, net of allowance for doubtful accounts of $2,365 and $3,418	70,797	45,323
Inventories	96,232	53,138
Prepaid expenses	6,273	7,939
Other current assets	41,569	39,865
Total current assets	325,718	299,306
Noncurrent Assets:
Property, plant and equipment, net	59,413	73,435
Operating right-of-use assets, net	10,399	9,056
Finance right-of-use assets, net	1,293	2,493
Intangible assets, net	11,694	14,343
Goodwill	35,104	40,279
Long-term investments	0	17,009
Other noncurrent assets	1,087	5,069
Total noncurrent assets	118,990	161,684
TOTAL ASSETS	444,708	460,990
Current Liabilities:
Accounts payable	39,349	28,024
Deferred revenue	2,273	2,936
Accrued expenses and other current liabilities	25,762	33,778
Finance lease liability	1,179	939
Operating lease liability	1,764	2,181
Acquisition-related contingent consideration obligation	65	206
Total current liabilities	70,392	68,064
Noncurrent Liabilities:
Finance lease liability	503	1,952
Operating lease liability	9,101	7,202
Acquisition-related contingent consideration obligation	99	354
Other noncurrent liabilities	581	651
Deferred income taxes	408	2,234
Total noncurrent liabilities	10,692	12,393
TOTAL LIABILITIES	81,084	80,457
Commitments and contingencies (Note 14)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 72,734 and 72,069 shares issued and outstanding	0	0
Additional paid-in capital	520,446	511,063
Accumulated other comprehensive loss	(18,435)	(10,077)
Accumulated deficit	(138,387)	(120,453)
Total stockholders' equity	363,624	380,533
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 444,708	$ 460,990

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 2,365	$ 3,418
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	72,734,000	72,069,000
Common stock, shares outstanding	72,734,000	72,069,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
NET REVENUES:
Total revenue	$ 387,479	$ 233,674	$ 171,721
COST OF PRODUCTS AND SERVICES SOLD	239,842	116,074	69,853
Gross profit	147,637	117,600	101,868
OPERATING EXPENSES:
Research and development	36,237	34,170	31,032
Sales and marketing	49,238	44,751	34,459
General and administrative	68,206	50,328	42,653
Loss on impairments	17,101
Change in the estimated fair value of acquisition-related contingent consideration	(188)	(1,485)	(1,099)
Total operating expenses	170,594	127,764	107,045
Operating loss	(22,957)	(10,164)	(5,177)
OTHER INCOME	6,481	872	1,653
Loss before income taxes	(16,476)	(9,292)	(3,524)
INCOME TAX EXPENSE	1,458	13,706	11,398
NET LOSS	$ (17,934)	$ (22,998)	$ (14,922)
LOSS PER SHARE:
BASIC	$ (0.25)	$ (0.32)	$ 0.22
DILUTED	$ (0.25)	$ (0.32)	$ 0.22
SHARES USED IN COMPUTING LOSS PER SHARE:
BASIC	72,505	71,981	67,505
DILUTED	72,505	71,981	67,505
Products and Services [Member]
NET REVENUES:
Total revenue	$ 378,047	$ 226,897	$ 166,381
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 9,432	$ 6,777	$ 5,340

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
NET LOSS	$ (17,934)	$ (22,998)	$ (14,922)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	(8,572)	(894)	3,273
Unrealized gain (loss) on marketable securities	214	(86)	(234)
COMPREHENSIVE LOSS	$ (26,292)	$ (23,978)	$ (11,883)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2019	$ 307,145		$ 401,814	$ (12,136)	$ (82,533)
Beginning Balance, Shares at Dec. 31, 2019		61,731
Common stock issued upon exercise of options	3,222		3,222
Common stock issued upon exercise of options, Shares		402
Vesting of restricted stock and performance stock units, Shares		653
Purchase and retirement of common shares	(2,088)		(2,088)
Purchase and retirement of common shares, Shares		(248)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200	95,036		95,036
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200, Shares		9,200
Stock-based compensation	7,139		7,139
Net loss	(14,922)				(14,922)
Currency translation adjustments	3,273			3,273
Unrealized gain (loss) on marketable securities	(234)			(234)
Ending Balance at Dec. 31, 2020	398,571		505,123	(9,097)	(97,455)
Ending Balance, Shares at Dec. 31, 2020		71,738
Common stock issued upon exercise of options	246		246
Common stock issued upon exercise of options, Shares		33
Vesting of restricted stock and performance stock units, Shares		451
Purchase and retirement of common shares	(2,113)		(2,113)
Purchase and retirement of common shares, Shares		(153)
Stock-based compensation	7,807		7,807
Net loss	(22,998)				(22,998)
Currency translation adjustments	(894)			(894)
Unrealized gain (loss) on marketable securities	(86)			(86)
Ending Balance at Dec. 31, 2021	380,533		511,063	(10,077)	(120,453)
Ending Balance, Shares at Dec. 31, 2021		72,069
Common stock issued upon exercise of options	$ 15		15
Common stock issued upon exercise of options, Shares	2	2
Vesting of restricted stock and performance stock units, Shares		992
Purchase and retirement of common shares	$ (2,254)		(2,254)
Purchase and retirement of common shares, Shares		(329)
Stock-based compensation	11,622		11,622
Net loss	(17,934)				(17,934)
Currency translation adjustments	(8,572)			(8,572)
Unrealized gain (loss) on marketable securities	214			214
Ending Balance at Dec. 31, 2022	$ 363,624		$ 520,446	$ (18,435)	$ (138,387)
Ending Balance, Shares at Dec. 31, 2022		72,734

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance of common stock in connection with public offering, net of commissions and expenses	$ 6,200

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
OPERATING ACTIVITIES:
Net income (loss)	$ (17,934)	$ (22,998)	$ (14,922)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation	11,622	7,807	7,139
Depreciation and amortization	15,308	11,658	9,387
Loss on impairments	17,101
Other non-cash amortization	228	837	327
Provision for doubtful accounts	(1,032)	(253)	941
Inventory reserve	(754)	6,731	736
Unrealized foreign currency (gain) loss	(161)	(210)	269
Interest expense on finance leases	94	82	72
Deferred income taxes	(1,651)	1,026	(392)
Loss on sale of fixed assets	729		114
Gain on sale of product line			(225)
Change in the estimated fair value of acquisition-related contingent consideration	(188)	(1,485)	(1,099)
Payment of acquisition-related contingent consideration		(142)	(496)
Changes in assets and liabilities
Accounts receivable	(25,162)	(6,451)	(2,324)
Inventories	(43,048)	(27,941)	(9,343)
Prepaid expenses and other assets	(7,091)	(8,674)	(104)
Accounts payable	3,963	3,234	7,379
Deferred revenue	(596)	(1,891)	1,051
Accrued expenses and other liabilities	1,370	3,288	7,297
Net cash (used in) provided by operating activities	(47,202)	(35,382)	5,807
INVESTING ACTIVITIES:
Purchases of investments	(22,873)	(25,822)	(90,137)
Proceeds from maturities and redemptions of investments	47,415	67,925	107,718
Proceeds from sale of assets	121
Purchases of property and equipment	(6,774)	(21,893)	(26,674)
Purchase of property and equipment under government contracts	(57,135)	(26,224)
Proceeds from funding under government contract	60,331	531
Purchase of patent and product rights			(2,250)
Acquisition of businesses, net of cash acquired			(3,037)
Other investing activities		(18)	351
Net cash (used in) provided by investing activities	21,085	(5,501)	(14,029)
FINANCING ACTIVITIES:
Cash payments for lease liabilities	(1,381)	(686)	(687)
Issuance of common stock in connection with public offering, net			95,036
Proceeds from exercise of stock options	15	246	3,222
Payment of acquisition-related contingent consideration	(208)	(264)	(3,004)
Repurchase of common stock	(2,254)	(2,113)	(2,088)
Net cash (used in) provided by financing activities	(3,828)	(2,817)	92,479
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(2,837)	(340)	830
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(32,782)	(44,040)	85,087
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	116,762	160,802	75,715
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 83,980	$ 116,762	$ 160,802

The Company

The Company	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. THE COMPANY: The primary goal of OraSure Technologies, Inc. (“OraSure” or “the Company”) is to empower the global community to improve health and wellness by providing access to accurate essential information through effortless tests, collection kits and services. OraSure's business consists of two segments: our “Diagnostics” segment, and our “Molecular Solutions” segment. The Company's Diagnostics business primarily consists of the development, manufacture, marketing and sale of simple, easy to use diagnostic products and specimen collection devices using the Company's proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Diagnostics business includes tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. The Company's COVID-19 and HIV products are also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and, in the case of the HIV product, as a self-test to individuals in a number of other countries. In 2022, after obtaining a CE mark, the Company launched the OraQuick ® HIV Self-Test, an oral swab in-home test for HIV-1 and HIV-2, in Europe, making it available in several European countries. Through the Company’s Diagnostics business the Company is also developing and commercializing products that measure adherence to HIV medications including pre-exposure prophylaxis ("PrEP"). The Company's Molecular Solutions business is operated by its wholly-owned subsidiaries, DNA Genotek Inc. ("DNAG"), Diversigen, Inc. ("Diversigen"), and Novosanis NV ("Novosanis"). The Company's Molecular Solutions business sells its products and services directly to its customers, primarily through its internal sales force in the U.S. domestic market, and in many international markets, also through distributors. The Company's products primarily consist of collection kits and services used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers. Most of the Company's Molecular Solutions revenues are derived from product sales to commercial customers and sales into the academic and research markets. A significant portion of the Company's total sales is from repeat customers in both markets. Molecular Solutions customers span the disease risk management, diagnostics, pharmaceutical, biotech, companion animal and environmental markets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, Diversigen, and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we”, “us”, “our”, or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as estimates related to taxes, contingent consideration, and performance-based compensation expense. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. Employee Retention Credit In December 2021, the Company applied for the Employee Retention Credit for payroll taxes paid in the first and second quarters of 2021 as provided by the Coronavirus Aid, Relief and Economic Security Act . The amount due from the Internal Revenue Service of $ 5,728 is recorded in other current assets in the Company's consolidated balance sheet as of December 31, 2022 and 2021. The amount was received in 2023. The credit is reported in the Company's consolidated statement of operations, for the year ended December 31, 2021, within cost of products and services sold, research and development, sales and marketing and general and administrative costs in the amounts of $ 2,536 , $ 1,134 , $ 924 , and $ 1,134 , respectively. Supplemental Cash Flow Information In 2022, 2021 and 2020 , the Company paid income taxes of $ 9,446 , $ 13,727 and $ 9,263 , respectively. The Company had account receivable write-offs of $ 2,296 , $ 115 , and $ 501 in 2022, 2021, and 2020, respectively. As of December 31, 2022, 2021 and 2020 , the Company had accruals for purchases of property and equipment of $ 227 , $ 8,166 and $ 802 , respectively. Investments The Company considers all investments in debt securities to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. The Company records an allowance for credit loss for the Company's available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value, and the probability that the scheduled cash payments will continue to be made. The following is a summary of the Company's available-for-sale securities as of December 31, 2022 and 2021: Amortized Gross Gross Fair Value December 31, 2022 Guaranteed investment certificates $ 22,109 $ — $ — $ 22,109 Corporate bonds 4,978 — ( 220 ) 4,758 Total available-for-sale securities $ 27,087 $ — $ ( 220 ) $ 26,867 December 31, 2021 Guaranteed investment certificates $ 33,249 $ — $ — $ 33,249 Corporate bonds 20,473 — ( 434 ) 20,039 Total available-for-sale securities $ 53,722 $ — $ ( 434 ) $ 53,288 At December 31, 2022, maturities of the Company's available-for-sale securities were as follows: Less than one year $ 27,087 $ — $ ( 220 ) $ 26,867 Greater than one year $ — $ — $ — $ — Fair Value of Financial Instruments As of December 31, 2022 and 2021, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and un-observable (i.e., supported by little or no market activity). All of the Company's available-for-sale debt securities are measured as Level 2 instruments as of December 31, 2022 and 2021. The Company's guaranteed investment certificates are measured as Level 1 instruments as of December 31, 2022 and 2021. Included in cash and cash equivalents at December 31, 2022 and 2021, was $ 1,730 and $ 1,160 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments. The Company offers a nonqualified deferred compensation plan for certain eligible employees and members of the Company's Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of December 31, 2022 and 2021 was $ 747 and $ 1,763 , respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other non-current assets with the same amounts included in accrued expenses and other non-current liabilities in the accompanying consolidated balance sheets. As further discussed in Note 3, Business Combinations, the Company has identified the Company's contingent consideration obligations as Level 3 liabilities due to significant inputs that are required to measure the fair value of these obligations. Accounts Receivable Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of the Company's customers and the Company's historical experience related to write-offs. Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of the Company's inventories are subject to expiration dating, which can be extended in certain circumstances. The Company continually evaluates quantities on hand and the carrying value of the Company's inventories to determine the need for net realizable value adjustments, based primarily on prior experience with consideration of expected changes in the business and estimated forecasts of product sales. The Company reserves for unidentified scrap or spoilage based on historical write-off rates. The Company also considers items identified through specific identification procedures in assessing the adequacy of the Company's reserve. Although the Company makes every effort to ensure the accuracy of its forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the carrying value of its inventories and reported operating results Property, Plant and Equipment Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are typically depreciated over twenty years , while computer equipment and software, machinery and equipment, and furniture and fixtures are depreciated over two to ten years . Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Intangible Assets Intangible assets consist of customer relationships, patents and product rights, acquired technology and trade names. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years . Impairment of Long-Lived Assets Long-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. See Note 6 for discussion of impairments recorded in 2022. Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if the Company believes that indicators of impairment exist. Current generally accepted accounting principles permit the Company to make a qualitative evaluation about the likelihood of goodwill impairment. If the Company concludes that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then the Company would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit. The Company performs an annual goodwill impairment assessment as of July 31 each year. Historically this involved a qualitative analysis that resulted in a conclusion that it was more likely than not that the fair value of the Company's reporting units is greater than their carrying value. A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount. Revenue Product sales . Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration the Company is entitled to, net of allowances for any discounts or rebates. The Company generally does not grant product return rights to the Company's customers, except for warranty returns and return rights on sales of the Company's OraQuick ® In-Home HIV test to the retail trade, and InteliSwab ® products to the retail trade and certain customers. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred. The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold. Service revenues. Service revenues represent microbiome laboratory testing and analytical services. The Company recognizes revenues when the Company satisfies its performance obligations for services rendered. Arrangements with multiple-performance obligations . In arrangements involving more than one performance obligation, which largely applies to the Company's service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable is determined using an observable cost plus margin approach. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied. Other revenues . Other revenues consist primarily of royalty income and funding from grants of research and development efforts. For the year ended December 31, 2021, other revenue also included cost reimbursements under a charitable support agreement which ended in June 2021. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Research and development grant revenue is recognized pursuant to International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance ("IAS 20") . The expenses are recorded in research and development expense and the reimbursements are recorded in other revenue. Funding of research and development efforts and charitable support reimbursements are recorded as the activities are performed in accordance with the respective agreements. Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2022 and 2021 included customer prepayments of $ 1,533 and $ 1,843 , respectively. Deferred revenue as of December 31, 2022 and 2021 also included $ 740 and $ 1,093 , respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of contract was determined based on expected revenues and revenue is recognized at that rate when the product is delivered to the customer. Financing and Payment . The Company's payment terms vary by the type and location of our customer and products or services offered. Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer. Practical expedients and exemptions . Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, the Company defers the cost of the commission and expenses it over the life of the related sales contract. Revenues by product . The following table represents total net revenues by product line: Years ended December 31, 2022 2021 2020 COVID-19 $ 243,325 $ 76,874 $ 50,927 Genomics 54,335 63,350 36,878 HIV 38,812 42,144 44,224 HCV 13,369 11,783 8,448 Risk assessment testing 10,269 9,678 9,194 Microbiome 7,503 7,944 5,474 Laboratory services 7,296 11,840 8,746 Other product and service revenues 3,138 3,284 2,490 Net product and services revenues $ 378,047 $ 226,897 $ 166,381 Royalty income 2,683 4,420 3,432 Other non-product revenues 6,749 2,357 1,908 Other revenues 9,432 6,777 5,340 Net revenues $ 387,479 $ 233,674 $ 171,721 Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Years ended December 31, 2022 2021 2020 United States $ 350,206 $ 188,383 $ 130,835 Europe 11,536 13,799 12,068 Other regions 25,737 31,492 28,818 $ 387,479 $ 233,674 $ 171,721 Customer and Vendor Concentrations. The Company had one customer that accounted for more than 57 % of the Company's consolidated accounts receivable as of December 31, 2022 and no ne as of December 31, 2021. The same customer accounted for approximately 58 % of the Company's consolidated revenues for the year ended December 31, 2022. The Company had no customers that accounted for more than 10% of the Company's consolidated net revenues for the years ended December 31, 2021 and 2020. The Company currently purchases certain products and critical components of the Company's products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of the Company's products to the Company's customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on the Company's business, as well as the Company's financial condition and results of operations. The Company’s Intercept i2 ® he collection device is manufactured and supplied under a long-term agreement with Thermo Fisher, the sole-source supplier for these products. DNAG has three long-term contract manufacturing relationships to supply virtually all of its products, including the Oragene ® product line. Many of the raw materials and components used in these products are also purchased from third parties, some of which are purchased from a single source supplier. The Company is actively seeking to qualify other suppliers that can manufacture and supply the raw materials and components for the DNAG products. Business Combinations and Contingent Consideration Acquired businesses are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to contingent consideration are recorded to the balance sheet at the date of acquisition based on their relative fair values. The purchase price allocation requires the Company to make significant estimates and assumptions, especially at the acquisition date, with respect to intangible assets. Although the Company believes the assumptions and estimates it has made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired companies and are inherently uncertain. The Company accounts for contingent consideration in accordance with applicable guidance provided within the business combination accounting standard. As part of the Company's consideration for the recent acquisitions, the Company is contractually obligated to pay certain consideration resulting from the outcome of future events. Therefore, the Company is required to update the Company's underlying assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in the Company's consolidated statements of operations. The Company's estimates of fair value are based on assumptions the Company believes to be reasonable, but the assumptions are uncertain and involve significant judgment by management. Updates to these assumptions could have a significant impact on the Company's results of operations in any given period and any updates to the fair value of the contingent consideration could differ materially from the previous estimates. Examples of critical estimates used in valuing certain intangible assets and contingent consideration include: • future expected cash flows from sales and acquired developed technologies; • the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio; • the probability of meeting the future events; and • discount rates used to determine the present value of estimated future cash flows. These estimates are inherently uncertain and unpredictable, and if different estimates were used the purchase price for the acquisition could be allocated to the acquired assets and liabilities differently from the allocation that the Company has made. In addition, unanticipated events and circumstances may occur, which may affect the accuracy or validity of such estimates, and if such events occur the Company may be required to record a charge against the value ascribed to an acquired asset or an increase in the amounts recorded for assumed liabilities . Research and Development Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred. Advertising Expenses Advertising costs are charged to expense as incurred. During 2022, 2021, and 2020, the Company incurred $ 4,849 , $ 5,103 , and $ 1,126 , respectively, in advertising expenses. Stock-Based Compensation The Company accounts for stock-based compensation to employees and directors using the fair value method. The Company recognizes compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. The Company recognizes compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, the Company issues new shares rather than purchase shares in the open market. Income Taxes The Company follows the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company assesses the realizability of the Company's net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, the Company reduces its net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the Company's net operating loss carryforwards. Foreign Currency Translation The assets and liabilities of the Company's foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in the Company's consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in the Company's consolidated statements of operations were $ 1,553 , $( 667 ) , and $( 337 ) for the years ended December 31, 2022, 2021, and 2020 , respectively. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is anti-dilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive. For the years ended December 31, 2022, 2021, and 2020 outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 436 , 769 , and 984 shares, respectively, were excluded from the computation of diluted loss per share. Accumulated Other Comprehensive Loss The Company classifies items of other comprehensive income (loss) by their nature and discloses the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of the Company's consolidated balance sheets. The Company has defined the Canadian dollar as the functional currency of the Company's Canadian subsidiary, DNAG, and the Company has defined the Euro as the functional currency of the Company's Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2022 consists of $ 18,215 of currency translation adjustments and $ 220 of net unrealized losses on marketable securities. Accumulated other comprehensive loss at December 31, 2021 consists of $ 9,643 of currency translation adjustments and $ 434 of net unrealized losses on marketable securities, which represents the fair market value adjustment for the Company's investments portfolio. Recent Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU were effective upon issuance and could be applied prospectively through December 31, 2022. The FASB issued an amendment, ASU 2022-06, Deferral of the Sunset Date of Topic 848, in December 2022, which, extends the date for prospective application to December 31, 2024. Management has evaluated this ASU and concluded that it will not have a material impact on the Company's Consolidated Financial Statements . Reclassifications Certain prior period amounts have been reclassified to conform to current year presentation. See Note 4 for discussion of the reclassification related to the U.S. Department of Defense contract.

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Business Combinations	3. BUSINESS COMBINATIONS UrSure On July 22, 2020, the Company acquired all of the outstanding stock of UrSure, Inc. (“UrSure”), pursuant to the terms of a merger agreement. The initial aggregate purchase price of this transaction was $ 3,000 , adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement. During the year ended December 31, 2020, the Company incurred a total of $ 393 of acquisition related costs, including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expense in the consolidated statement of operations for the year ended December 31, 2020. Pursuant to the Company's acquisition agreement, the Company was to pay up to an additional $ 28,000 of contingent consideration over the three years following the acquisition date based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, and the achievement of certain clinical milestones associated with the development of certain new technology. The Company, with the assistance of an independent valuation specialist, determined the estimated acquisition-date fair value of the acquisition-related contingent consideration of $ 3,440 . The fair value was determined using a probability-weighted model based on the Company's assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including the likelihood of the achievement of clinical milestones and revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. As of December 31, 2022, it is not likely the Company will be required to make a material payment. The following table represents the change in contingent consideration: Estimated fair value of contingent consideration as of acquisition date $ 3,440 Change in fair value during the period ( 989 ) Balance as of December 31, 2020 2,451 Payments made during the period ( 406 ) Change in fair value during the period ( 1,485 ) Balance as of December 31, 2021 560 Payments made during the period ( 208 ) Change in fair value during the period ( 188 ) Balance as of December 31, 2022 $ 164 The change in fair value during the years ended December 31, 2022, 2021 and 2020 is a result of delays in achieving certain product development milestones and a decrease in associated revenue forecasts as result of these delays. Revenues from UrSure primarily consist of grant money received to fund the development of certain new technology. Effective as of July 22, 2020, the financial results of UrSure are included in the Company's Diagnostics segment. The Company finalized its valuation of the assets acquired and liabilities assumed. The total consideration of $ 3,037 was allocated to assets acquired and liabilities assumed as of the acquisition date as follows: Assets Acquired Accounts receivable $ 285 Other current assets 24 Other assets 6 Intangibles 3,600 Goodwill 3,586 Total assets acquired 7,501 Liabilities Assumed Current liabilities 335 Deferred tax liability 689 Total liabilities assumed 1,024 Net Assets Acquired 6,477 Fair value of contingent consideration ( 3,440 ) Net Cash Paid (net of cash acquired of $ 111 ) $ 3,037 The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, which is subject to amortization on a straight-line basis and is being amortized over a ten year estimated useful life. The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of UrSure. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that the Company expects to achieve as a result of the acquisition. The Company believes the goodwill related to the acquisition was a result of gaining a complementary product offering that will enable the Company to leverage those products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to the Company's Diagnostics segment.

Government Capital Contracts

Government Capital Contracts	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Government Capital Contracts	4. GOVERNMENT CAPITAL CONTRACTS: In September 2021, the Company entered into an agreement for $ 109,000 in funding from the U.S. Department of Defense (the “DOD”), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for the Company's InteliSwab ® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. Funding will be paid to the Company based on achievement of milestones expected to occur through December 2023 for the design, acquisition, installation, qualification and acceptance of the manufacturing equipment, as set forth in the agreement. In accordance with the milestone payment schedule, 15 % of the total will not be funded until the completion of the final validation testing, which is scheduled to occur in late 2023. The Company began making payments to vendors for the capital project during the fourth quarter of 2021. The Company began receiving funds from the DOD in January 2022 and has received $ 60,331 as of the date of this report. The remaining $ 48,669 is expected to be collected within the next year. Activity for these capital contracts is accounted for pursuant to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance . Funding received in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows; and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows. Property, plant and equipment in the amount of $ 14,729 that was recorded on the Company's consolidated balance sheet as of December 31, 2021 was reclassified in 2022 as the assets were allocated to the DOD build out. The consolidated balance sheet as of December 31, 2021 has been updated to reflect a reduction of $ 14,729 in property, plant and equipment and an increase in other current assets of $ 10,875 and other noncurrent assets of $ 3,854 for amounts due from DOD. The respective investing activities on the consolidated cash flows for the year ended December 31, 2021 have also been reclassified. The DOD also reimburses the Company for certain engineering consulting costs. These expenses are reflected in research and development expenses as incurred with the corresponding amount presented in other income. For the year ended December 31, 2022, $ 1,422 was recorded in research and development expenses and other income. Amounts earned in excess of the Company's expected costs for the project for project management are recognized straight-line in other income over the term of the government contract. The Company recognized $ 2,246 and $ 561 of such income, which is reported as other income in the Company's consolidated statement of operations for the year ended December 31, 2022 and 2021, respectively. Additionally, during 2021, the Company received $ 531 in funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development, for the purchase of machinery and equipment as part of an expansion of manufacturing operations in Pennsylvania. All related purchases were completed in 2021. The balances corresponding to government contracts included in the Company's consolidated balance sheet are as follows: December 31, December 31, Other current assets: Billed receivables $ — $ 9,913 Unbilled receivables 27,013 20,591 Total other current assets 27,013 30,504 Other non-current assets — 3,854 Accrued expenses and other current liabilities $ ( 318 ) $ ( 8,103 ) The activity corresponding to the government contracts included in the Company's consolidated statements of cashflows is as follows: December 31, December 31, Cost of assets, cumulative $ 83,359 $ 26,224 Reduction for funding earned to date, not yet received ( 22,497 ) ( 25,693 ) Reduction for funding received to date ( 60,862 ) ( 531 ) Total property, plant and equipment, net $ — $ —

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	5. INVENTORIES: December 31, 2022 2021 Raw materials $ 42,445 $ 33,168 Work in process 2,335 2,252 Finished goods 51,452 17,718 $ 96,232 $ 53,138 During 2022, 2021, and 2020, the Company recorded adjustments to inventory which had a cost of $ 15,618 , $ 13,400 , and $ 2,564 , respectively. The adjustments in 2021 included a write-off of $ 3,008 of COVID-19 antibody inventory, which the Company does not believe the Company can sell as a result of the decision to no longer pursue an EUA for the ELISA antibody test. Additionally, a significant portion of the Company's 2022 and 2021 adjustments were related to production and tech-transfer issues associated with the Company's COVID-19 rapid test.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	6. PROPERTY, PLANT AND EQUIPMENT: December 31, 2022 2021 Land $ 1,118 $ 1,118 Buildings and improvements 35,582 35,420 Machinery and equipment 60,725 57,919 Computer equipment and software 16,681 14,700 Furniture and fixtures 4,064 4,228 Construction in progress 11,124 21,207 129,294 134,592 Less accumulated depreciation ( 69,881 ) ( 61,157 ) $ 59,413 $ 73,435 During the year ended December 31, 2022, management determined several manufacturing lines and associated supporting assets will not be utilized due to changes in forecasted demand for the products the lines are intended to produce. As a result of this decision, the Company determined that the carrying values of the equipment are not recoverable and recorded aggregate pre-tax asset impairment charges of $ 8,585 and $ 4,912 to the Molecular Solutions and Diagnostics segments, respectively, to write the assets down to their estimated fair values. This resulted in the assets being fully impaired. This charge is reported within loss on impairments in the consolidated statement of operations. The Company estimated the fair value of the impaired long-lived assets using a market approach, which required the Company to estimate the value that would be received for the equipment in the most advantageous market for that equipment in an orderly transaction between market participants. Due to the extremely specialized nature of the manufacturing equipment and various market data points, the estimated fair value was not significant. The Company's fair value estimates were representative of Level 3 measurements within the fair value hierarchy due to the significant level of estimation involved and the lack of transparency as to the inputs used. Depreciation expense was $ 11,740 , $ 7,498 , and $ 5,514 for 2022, 2021, and 2020 , respectively. See Note 4 for discussion of prior year reclassification.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	7. GOODWILL AND OTHER INTANGIBLE ASSETS: The following table represents total goodwill by operating segment: December 31, 2022 2021 Diagnostics $ — $ 3,604 Molecular Solutions 35,104 36,675 $ 35,104 $ 40,279 The changes in goodwill are as follows: December 31, 2022 2021 Balance as of January 1 $ 40,279 $ 40,351 Impairment ( 3,604 ) — Purchase price adjustment — 18 Change related to foreign currency translation ( 1,571 ) ( 90 ) Balance as of December 31 $ 35,104 $ 40,279 During the second quarter of 2022, the Company determined that a triggering event occurred in relation to the depressed market price of the Company's common stock and corresponding decline in the Company's market capitalization. As a result, the Company performed an interim quantitative goodwill impairment test and concluded that the carrying value of the Company's Diagnostics reporting unit exceeded its estimated fair value and the goodwill balance for that segment was fully impaired. The Company recognized a pre-tax impairment charge of $ 3,604 during the year ended December 31, 2022, which is reported in loss on impairments in the Company's consolidated statement of operations. The Company's quantitative goodwill impairment test concluded that the carrying value of the Company's Molecular Solutions reporting unit exceeded its estimated fair value and no impairment of the related goodwill exists. Intangible assets consist of the following: December 31, 2022 Amortization Gross Accumulated Amortization Net Customer relationships 10 $ 14,286 $ ( 11,011 ) $ 3,275 Patents and product rights 5 7,620 ( 6,615 ) 1,005 Developed technology 7 - 10 15,478 ( 9,940 ) 5,538 Tradename 5 - 15 5,387 ( 3,511 ) 1,876 $ 42,771 $ ( 31,077 ) $ 11,694 December 31, 2021 Amortization Gross Accumulated Net Customer relationships 10 $ 15,016 $ ( 11,205 ) $ 3,811 Patents and product rights 5 7,785 ( 6,241 ) 1,544 Developed technology 7 - 10 16,293 ( 9,725 ) 6,568 Tradename 5 - 15 5,661 ( 3,241 ) 2,420 $ 44,755 $ ( 30,412 ) $ 14,343 Amortization expense for 2022, 2021, and 2020 was $ 2,269 , $ 3,260 , and $ 3,246 , respectively. Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows: 2023 $ 2,221 2024 2,183 2025 1,947 2026 1,591 2027 1,520 Beyond 2,232 $ 11,694

Accrued Expenses And Other Curr

Accrued Expenses And Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES: December 31, 2022 2021 Payroll and related benefits $ 14,103 $ 15,570 Commitment to purchase under government contract — 8,103 Professional fees 4,685 3,335 Sales tax payable 1,519 2,227 Other 5,455 4,543 $ 25,762 $ 33,778

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Leases	9. LEASES: The Company determines whether an arrangement is a lease at inception. The Company has operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of December 31, 2022, the Company is the lessee in all agreements. The Company's leases have remaining lease terms of 1 to 10 years , some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year. The Company presents the operating right-of-use asset amortization and the change in operating lease liabilities on the same line item, other non-cash amortization on the statement of cash flows. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company has lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, the Company accounts for lease components separately from non-lease components. During 2021, the Company entered into various purchase agreements for the Company's Molecular Solutions business which include a finance lease component for the use of specialized molds made and used by the vendor for purposes of manufacturing the goods to be purchased. The Company recorded an aggregate ROU asset and offsetting lease liability of $ 2,074 upon commencement of these contracts. The consideration to be paid under the agreements is variable based on the amounts purchased with a fixed amount charged if specified purchase minimums are not met. Only the fixed amount has been included in the measurement of the finance right-of-use asset and lease liability, and the variable costs are recognized as purchases are made within cost of products and services sold in the Company's consolidated statements of operations. The consideration for the contract has been allocated between the lease and non-lease components based on their relative estimated stand-alone selling prices. The components of lease expense are as follows: Years ended December 31, 2022 2021 2020 Operating lease cost $ 2,910 $ 2,226 $ 1,291 Variable and short-term lease cost 521 201 — Finance lease cost: Amortization of right-of use assets 1,299 900 627 Interest on lease liabilities 94 82 72 Total finance lease cost 1,393 982 699 Total lease cost $ 4,824 $ 3,409 $ 1,990 Supplemental cash flow information related to leases is as follows: Years ended December 31, 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,209 $ 3,733 $ 1,280 Operating cash flows from financing leases 94 82 72 Financing cash flows from financing leases 1,381 686 687 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations 3,963 6,480 498 Right-of-use assets obtained in exchange for finance lease obligations 117 2,074 46 Supplemental balance sheet information related to leases is as follows: December 31, 2022 2021 Operating Leases Right-of-use assets $ 10,399 $ 9,056 Lease liabilities: Current lease liabilities 1,764 2,181 Non-current lease liabilities 9,101 7,202 Total operating lease liabilities $ 10,865 $ 9,383 Finance Leases Right-of-use assets $ 1,293 $ 2,493 Lease liabilities: Current lease liabilities 1,179 939 Non-current lease liabilities 503 1,952 Total finance lease liabilities $ 1,682 $ 2,891 Weighted Average Remaining Lease Term Weighted-average remaining lease term—operating leases 6.24 years 5.26 years Weighted-average remaining lease term—finance leases 1.33 years 2.21 years Weighted Average Discount Rate Weighted-average discount rate—operating leases 4.06 % 3.90 % Weighted-average discount rate—finance leases 3.44 % 3.57 % As of December 31, 2022, minimum lease payments by period are expected to be as follows: Finance Operating 2023 $ 1,216 $ 1,898 2024 505 2,311 2025 20 1,928 2026 12 1,710 2027 — 1,544 Thereafter — 3,083 Total minimum lease payments 1,753 12,474 Less: imputed interest ( 71 ) ( 1,609 ) Present value of lease liabilities $ 1,682 $ 10,865

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES: Income (loss) before income tax expense consists of the following: Years Ended December 31, 2022 2021 2020 United States $ ( 7,912 ) $ ( 60,500 ) $ ( 47,995 ) Foreign ( 8,564 ) 51,208 44,471 $ ( 16,476 ) $ ( 9,292 ) $ ( 3,524 ) The components of income tax expense (benefit) are as follows: Years Ended December 31, 2022 2021 2020 Current Federal $ — $ — $ — State 955 163 ( 106 ) Foreign 2,154 12,517 11,896 3,109 12,680 11,790 Deferred Federal ( 2,250 ) ( 10,318 ) ( 20,946 ) State ( 633 ) ( 965 ) ( 1,053 ) Foreign ( 2,617 ) ( 151 ) ( 410 ) ( 5,500 ) ( 11,434 ) ( 22,409 ) Increase (decrease) in valuation allowance 3,849 12,460 22,017 ( 1,651 ) 1,026 ( 392 ) Total income tax expense $ 1,458 $ 13,706 $ 11,398 For the years ended December 31, 2022, 2021, and 2020 the Company recorded foreign income tax expense of $ 503 , $ 13,543 , and $ 12,185 , respectively. The Company's 2022 income tax expense is comprised of $ 1,703 of Canadian withholding taxes paid on the repatriation of Canadian earnings which occurred in the first quarter of 2022, $ 955 of U.S. state income taxes, and a foreign income tax benefit of $ 1,200 associated with the Company's Canadian subsidiary. The Company's 2021 income tax expense is comprised of U.S. state income taxes of $ 163 and foreign tax expense associated with the Company's Canadian subsidiary of $ 13,543 . The Company's 2020 income tax expense is comprised of a U.S. state income tax benefit of a $ 794 and foreign tax expense associated with the Company's Canadian subsidiary of $ 12,192 . A reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate for each of the years ended December 31, 2022, 2021, and 2020 is as follows: 2022 2021 2020 Statutory U.S. federal income tax rate 21.0 % 21.0 % 21.0 % Nondeductible executive compensation ( 5.5 ) ( 6.1 ) ( 0.9 ) Impact of share-based payment awards ( 4.8 ) ( 3.3 ) ( 12.4 ) Tax effect of foreign items ( 5.7 ) ( 30.8 ) ( 70.7 ) State income taxes, net of federal benefit ( 0.8 ) 6.8 26.0 U.S. and foreign tax credits 3.6 2.5 34.9 Nondeductible transaction costs — — ( 2.8 ) Nondeductible expenses and other 7.0 ( 4.0 ) ( 2.6 ) NOL adjustment due to change in GILTI regulations — — 308.9 Change in valuation allowance, federal and state ( 23.7 ) ( 133.6 ) ( 624.8 ) Effective tax rate ( 8.9 ) % ( 147.5 ) % ( 323.4 ) % Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of the Company's deferred tax assets (liabilities) as of December 31, 2022 and 2021 are as follows: 2022 2021 Deferred tax assets (liabilities): Net operating loss carryforwards $ 39,783 $ 44,191 Inventories 4,504 4,642 Capitalized research and development costs 6,505 453 Accruals and reserves currently not deductible 2,799 3,245 Acquired intangible assets ( 2,641 ) ( 3,117 ) Depreciation and amortization ( 6,227 ) ( 8,536 ) Right-of-use assets ( 2,775 ) ( 2,777 ) Lease liabilities 2,990 2,957 Stock-based compensation 3,032 1,891 Tax credit carryforwards 4,509 3,855 Net deferred tax asset 52,479 46,804 Valuation allowance ( 52,887 ) ( 49,038 ) Net deferred tax liability $ ( 408 ) $ ( 2,234 ) In assessing the realizability of the Company's deferred tax asset, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, the Company established a full valuation allowance against the Company's U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2022 and 2021 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2022, 2021, and 2020. The Company's Federal NOL carryforwards expire as follows: Year of Expiration NOLs 2030 - 2033 $ 36,107 2034 - 2037 12,055 Non-Expiring 117,885 $ 166,047 The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. The Company does not believe that there is a Section 382 limitation that will impair the Company's future ability to utilize NOLs to offset the Company's future taxable income. The Company continues to review ownership changes on an annual basis and the Company does not believe it has had a subsequent ownership change that would impact the NOLs. In January 2022, approximately $ 65,000 was repatriated from the Company's Canadian subsidiary as a one-time event. Associated with this repatriation the Company paid $ 1.7 million in Canadian withholding tax which is included in the Company's foreign income tax expense within the table further above. It is still the Company's intention to continue to permanently reinvest the historical undistributed earnings of the Company's foreign subsidiary to the extent that the Company will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the foreign subsidiary as of December 31, 2022. As of December 31, 2022 , the Company's gross unrecognized tax benefits totaled $ 373 , and based upon the valuation allowance for the Company's U.S. operations, the recognition of any tax benefit would not impact the Company's effective tax rate. The Company records interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2022, 2021, and 2020. As a result of the Company's net operating loss carryforward position, the Company is subject to audit by the Internal Revenue Service since the Company's inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2022. A reconciliation of the Company's unrecognized tax benefits is as follows: 2022 2021 2020 Balance as of January 1 $ 805 $ 1,172 $ 1,308 Additions for tax positions of prior periods 1 1 1 Reductions for tax positions of prior periods ( 433 ) ( 368 ) ( 137 ) Balance as of December 31 $ 373 $ 805 $ 1,172

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders' Equity	11. STOCKHOLDERS’ EQUITY: Stock-Based Awards The Company grants stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. As of December 31, 2022 , 3,921 shares were available for future grants under the Stock Plan. Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including the Company's officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years , with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years. The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions: Years Ended December 31, Black-Scholes Option Valuation Assumptions 2022 2021 2020 Risk-free interest rate (1) 1.65 % 0.47 % 1.33 % Expected dividend yield — — — Expected stock price volatility (2) 50 % 50 % 42 % Expected life of stock options (in years) (2) 5 5 5 (1) Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options. (2) Based upon historical experience. The weighted-average grant date fair value of stock options granted during the years ended December 31, 2022, 2021, and 2020 was $ 4.15 , $ 6.14 and $ 2.79 , respectively. Compensation expense recognized in the financial statements related to stock options was $ 1,515 , 1,063 , and $ 892 for the years ended December 31, 2022, 2021, and 2020, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021, and 2020 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $ 4 , $ 130 , and $ 3,117 , respectively. The following table summarizes the stock option activity under the Stock Plan: Options Weighted- Weighted- Aggregate Intrinsic Value Outstanding on January 1, 2022 1,410 $ 10.73 Granted 589 8.86 Exercised ( 2 ) 7.17 Expired ( 28 ) 10.01 Forfeited ( 211 ) 9.63 Outstanding on December 31, 2022 1,758 $ 10.25 6.54 $ — Vested or expected to vest as of December 31, 2022 1,633 $ 10.29 7.03 $ — Exercisable on December 31, 2022 1,045 $ 10.67 5.11 $ — As of December 31, 2022 , there was $ 2,583 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.6 years. Net cash proceeds from the exercise of stock options were $ 15 , $ 246 and $ 3,222 for the years ended December 31, 2022, 2021, and 2020 , respectively. As a result of the Company's net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods. The following table summarizes information about stock options outstanding as of December 31, 2022: Options outstanding Options exercisable Range of exercise prices Number Weighted- Weighted- Number Weighted- $ 5.37 -$ 8.86 1,036 7.2 $ 7.83 435 $ 6.83 $ 8.87 -$ 13.31 362 4.8 10.67 357 10.64 $ 14.95 -$ 22.43 360 6.5 16.79 253 17.30 1,758 6.5 $ 10.25 1,045 $ 10.67 The Stock Plan also permits the Company to grant restricted shares and restricted units of the Company's common stock to eligible employees, including officers, and the Company's outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by the Company's Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the vesting restrictions lapse. Compensation cost of $ 9,169 , $ 4,094 and $ 4,094 related to restricted shares was recognized during the years ended December 31, 2022, 2021, and 2020, respectively. The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan: Units Weighted- Issued and unvested, January 1, 2022 701 $ 11.53 Granted 2,995 6.45 Vested ( 750 ) 9.50 Forfeited ( 373 ) 9.47 Issued and unvested, December 31, 2022 2,573 $ 6.51 Issued and expected to vest, December 31, 2022 2,538 $ 6.53 As of December 31, 2022 , there was $ 11,185 of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 1.8 years. In connection with the vesting of restricted shares during the years ended December 31, 2022, 2021, and 2020, the Company purchased and immediately retired 241 , 107 and 127 shares with aggregate values of $ 1,621 , $ 1,417 and $ 1,219 , respectively, in satisfaction of minimum tax withholding and exercise obligations. The Company grants performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in the Company's service for three years from the grant date. Prior to 2021, performance during the one-year period was based on a one-year income before tax target. Performance during the three-year period was based on achievement of a three-year compound annual growth rate for consolidated revenues. In 2021 and 2022, performance shares were granted based on the achievement of three-year cumulative revenue metrics with a market-based condition, or a total shareholder return modifier. PSUs are converted into shares of the Company's common stock once vested and the number of shares actually earned at the end of the performance period will vary, based on actual performance, from 0 % to 200 % of the target number of performance share units granted. Upon grant of the PSUs, the Company recognizes compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. Compensation cost of $ 938 , $ 2,650 and $ 2,153 related to the PSUs was recognized during the years ended December 31, 2022, 2021, and 2020, respectively. The following table summarizes PSU activity under the Stock Plan: Units Weighted- Issued and unvested, January 1, 2022 622 $ 9.88 Granted (1) 532 8.86 Performance adjustment (2) 36 N/A Vested ( 241 ) 11.09 Forfeited ( 234 ) 10.50 Issued and unvested, December 31, 2022 715 $ 6.86 Issued and expected to vest, December 31, 2022 698 $ 6.82 (1) Grant activity for all PSUs disclosed at target. (2) Reflects the performance adjustment based on actual performance measured at the end of the performance period. As of December 31, 2022 , there was $ 316 of unrecognized compensation expense related to unvested performance stock units that is expected to be recognized over a weighted average period of 1.6 years. In connection with the vesting of performance stock units during the year ended December 31, 2022, 2021 and 2020, we purchased and immediately retired 88 , 46 , and 121 shares with aggregate values of $ 633 , $ 696 and $ 869 , respectively. Public Offering On June 1, 2020, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group LLC, as representatives of several underwriters, relating to the issuance and sale of 8,000 shares of the Company's common stock. The price to the public in the offering was $ 11.00 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,200 shares of common stock. On June 3, 2020, the Company announced the full exercise by the underwriters of their option to purchase these additional shares. The offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-228877) the Company had previously filed with the SEC, and a prospectus supplement thereunder. The net proceeds from the offering were approximately $ 95,000 after deducting underwriting discounts and offering expenses paid by the Company. Share Repurchase Program On August 5, 2008, the Company's Board of Directors approved a share repurchase program pursuant to which the Company is permitted to acquire up to $ 25,000 of the Company's outstanding common shares. No shares were purchased and retired in 2022, 2021, and 2020 .

Transition Costs

Transition Costs	12 Months Ended
	Dec. 31, 2022
Transition Costs [Abstract]
Transition Costs	12. TRANSITION COSTS On December 31, 2021, the Company's Board of Directors approved the termination of Stephen S. Tang, the Company’s President and Chief Executive Officer, without cause under his existing employment agreement with the Company, with such termination effective as of March 31, 2022. On January 2, 2022, Dr. Tang and the Company entered into a Transition Agreement providing for the terms of the cessation of Dr. Tang’s employment with the Company, including the cessation of his service as President and Chief Executive Officer of the Company and as a member of the Board. Under the Transition Agreement, Dr. Tang’s service to the Company in all capacities ended on March 31, 2022. Pursuant to the Transition Agreement, Dr. Tang received severance of $ 1,569 , which was accrued in the consolidated financial statements at December 31, 2021 and paid in April 2022. Additionally, in accordance with his Transition Agreement, certain of his unvested time-vesting restricted stock awards and unvested PSUs that were outstanding at March 31, 2022 vested on April 8, 2022. His remaining unvested time-vesting restricted stock awards and PSUs were forfeited on March 31, 2022. These payments, rights and benefits are substantially similar to the severance benefits contemplated by his previous employment agreement in respect to a termination without cause thereunder. In aggregate, the Company recognized $ 1,508 of expense in relation to Dr. Tang's stock compensation for the year ended December 31, 2022.

Business Segment Information

Business Segment Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Business Segment Information	13. BUSINESS SEGMENT INFORMATION: The Company's business consists of two segments, which are described in Note 1: the Company's “Diagnostics” segment and the Company's “Molecular Solutions” segment. The Company organized its operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). The Company evaluates performance of its operating segments based on revenue and operating income. The Company does not allocate interest income, interest expense, other income, other expenses or income taxes to its operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated. The following table summarizes operating segment information for the years ended December 31, 2022, 2021, and 2020, and asset information as of December 31, 2022 and 2021: Years ended December 31, 2022 2021 2020 Net revenues: Diagnostics $ 303,673 $ 90,040 $ 65,240 Molecular Solutions 83,806 143,634 106,481 Total $ 387,479 $ 233,674 $ 171,721 Operating income (loss): Diagnostics $ ( 598 ) $ ( 57,177 ) $ ( 43,156 ) Molecular Solutions ( 22,359 ) 47,013 37,979 Total $ ( 22,957 ) $ ( 10,164 ) $ ( 5,177 ) Depreciation and amortization: Diagnostics $ 8,099 $ 4,325 $ 3,345 Molecular Solutions 7,209 7,333 6,042 Total $ 15,308 $ 11,658 $ 9,387 Capital expenditures: Diagnostics (1) $ 3,644 $ 12,265 $ 17,860 Molecular Solutions 3,130 9,628 8,814 Total $ 6,774 $ 21,893 $ 26,674 (1) Excludes $ 57,135 and $ 26,224 for purchases of property and equipment under government contracts for the years ended December 31, 2022 and 2021 respectively. No purchases of property and equipment under government contracts were made in 2020. December 31, 2022 2021 Total assets: Diagnostics $ 279,994 $ 209,674 Molecular Solutions 164,714 251,316 Total $ 444,708 $ 460,990 The following table represents total long-lived assets by geographic area: December 31, 2022 2021 United States $ 60,751 $ 72,376 Canada 8,526 11,488 Other regions 1,828 1,120 $ 71,105 $ 84,984

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. COMMITMENTS AND CONTINGENCIES: Purchase Commitments As of December 31, 2022 , the Company had manufacturing agreements with certain third party vendors, in which minimum purchase commitments are required. If the minimum commitments are not achieved, the Company will be required to make annual penalty payments over the next three years. Based on current forecasts, these penalties aggregate to approximately $ 1,143 and are accrued for in the consolidated balance sheet. These estimated penalties can fluctuate based on changes in forecasted demand. The table below represents an estimate of future purchases under those agreements. 2023 $ 21,710 2024 9,695 2025 6,928 2026 — 2027 — $ 38,333 Litigation From time to time, the Company is involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on the Company's future financial position or results of operations. Spectrum Patent Litigation a motion for summary judgment of noninfringement. DNAG oppossed the motion. Briefing is complete and the motion remains pendng. The final pretrial conference is set for September 7, 2023. The Patent and Trademark Office instituted review of the second patent on February 10, 2023, scheduling a hearing for November 14, 2023.

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Plans	15. RETIREMENT PLANS: Substantially all of the Company's U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for the Company to match employee contributions up to $ 4 per year. The Company contributed $ 1,763 , $ 1,295 and $ 994 to the 401(k) Plan, net of forfeitures, in 2022, 2021, and 2020, respectively. In addition to the Company's 401(k) plan, the Company offers a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. The Company also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2022 and 2021, the value of the assets associated with this plan was $ 747 and $ 1,763 , respectively, and is included in current assets and other assets in the Company's consolidated balance sheets. The Company's obligation related to the deferred compensation plan is included in accrued expenses and other liabilities in the Company's consolidated balance sheets. As of December 31, 2022 and 2021, the Company's total obligation under this plan was $ 747 and $ 1,763 , respectively. Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Canada Revenue Agency. The RRSP also provides for DNAG to match employee contributions up to $ 4 CAD per year. The Company contributed $ 453 , $ 448 and $ 366 to the RRSP in 2022, 2021, and 2020 , respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	16. SUBSEQUENT EVENTS: On February 14, 2023, the Company announced a 11 % reduction in its non-production workforce. This will be accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations , and the expense will primarily be recorded in the first quarter of 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, Diversigen, and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we”, “us”, “our”, or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as estimates related to taxes, contingent consideration, and performance-based compensation expense. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
Employee Retention Credit	Employee Retention Credit In December 2021, the Company applied for the Employee Retention Credit for payroll taxes paid in the first and second quarters of 2021 as provided by the Coronavirus Aid, Relief and Economic Security Act . The amount due from the Internal Revenue Service of $ 5,728 is recorded in other current assets in the Company's consolidated balance sheet as of December 31, 2022 and 2021. The amount was received in 2023. The credit is reported in the Company's consolidated statement of operations, for the year ended December 31, 2021, within cost of products and services sold, research and development, sales and marketing and general and administrative costs in the amounts of $ 2,536 , $ 1,134 , $ 924 , and $ 1,134 , respectively.
Supplemental Cash Flow Information	Supplemental Cash Flow Information In 2022, 2021 and 2020 , the Company paid income taxes of $ 9,446 , $ 13,727 and $ 9,263 , respectively. The Company had account receivable write-offs of $ 2,296 , $ 115 , and $ 501 in 2022, 2021, and 2020, respectively. As of December 31, 2022, 2021 and 2020 , the Company had accruals for purchases of property and equipment of $ 227 , $ 8,166 and $ 802 , respectively.
Investments	Investments The Company considers all investments in debt securities to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. The Company records an allowance for credit loss for the Company's available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value, and the probability that the scheduled cash payments will continue to be made. The following is a summary of the Company's available-for-sale securities as of December 31, 2022 and 2021: Amortized Gross Gross Fair Value December 31, 2022 Guaranteed investment certificates $ 22,109 $ — $ — $ 22,109 Corporate bonds 4,978 — ( 220 ) 4,758 Total available-for-sale securities $ 27,087 $ — $ ( 220 ) $ 26,867 December 31, 2021 Guaranteed investment certificates $ 33,249 $ — $ — $ 33,249 Corporate bonds 20,473 — ( 434 ) 20,039 Total available-for-sale securities $ 53,722 $ — $ ( 434 ) $ 53,288 At December 31, 2022, maturities of the Company's available-for-sale securities were as follows: Less than one year $ 27,087 $ — $ ( 220 ) $ 26,867 Greater than one year $ — $ — $ — $ —
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of December 31, 2022 and 2021, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and un-observable (i.e., supported by little or no market activity). All of the Company's available-for-sale debt securities are measured as Level 2 instruments as of December 31, 2022 and 2021. The Company's guaranteed investment certificates are measured as Level 1 instruments as of December 31, 2022 and 2021. Included in cash and cash equivalents at December 31, 2022 and 2021, was $ 1,730 and $ 1,160 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments. The Company offers a nonqualified deferred compensation plan for certain eligible employees and members of the Company's Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of December 31, 2022 and 2021 was $ 747 and $ 1,763 , respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other non-current assets with the same amounts included in accrued expenses and other non-current liabilities in the accompanying consolidated balance sheets. As further discussed in Note 3, Business Combinations, the Company has identified the Company's contingent consideration obligations as Level 3 liabilities due to significant inputs that are required to measure the fair value of these obligations.
Accounts Receivable	Accounts Receivable Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of the Company's customers and the Company's historical experience related to write-offs.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of the Company's inventories are subject to expiration dating, which can be extended in certain circumstances. The Company continually evaluates quantities on hand and the carrying value of the Company's inventories to determine the need for net realizable value adjustments, based primarily on prior experience with consideration of expected changes in the business and estimated forecasts of product sales. The Company reserves for unidentified scrap or spoilage based on historical write-off rates. The Company also considers items identified through specific identification procedures in assessing the adequacy of the Company's reserve.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are typically depreciated over twenty years , while computer equipment and software, machinery and equipment, and furniture and fixtures are depreciated over two to ten years . Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.
Intangible Assets	Intangible Assets Intangible assets consist of customer relationships, patents and product rights, acquired technology and trade names. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years .
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. See Note 6 for discussion of impairments recorded in 2022.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if the Company believes that indicators of impairment exist. Current generally accepted accounting principles permit the Company to make a qualitative evaluation about the likelihood of goodwill impairment. If the Company concludes that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then the Company would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit. The Company performs an annual goodwill impairment assessment as of July 31 each year. Historically this involved a qualitative analysis that resulted in a conclusion that it was more likely than not that the fair value of the Company's reporting units is greater than their carrying value. A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.
Revenue	Revenue
Product Sales	Product sales . Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration the Company is entitled to, net of allowances for any discounts or rebates. The Company generally does not grant product return rights to the Company's customers, except for warranty returns and return rights on sales of the Company's OraQuick ® In-Home HIV test to the retail trade, and InteliSwab ® products to the retail trade and certain customers. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred. The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold.
Service Revenues	Service revenues. Service revenues represent microbiome laboratory testing and analytical services. The Company recognizes revenues when the Company satisfies its performance obligations for services rendered.
Arrangements with Multiple-performance Obligations	Arrangements with multiple-performance obligations . In arrangements involving more than one performance obligation, which largely applies to the Company's service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable is determined using an observable cost plus margin approach. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied.
Other Revenues	Other revenues . Other revenues consist primarily of royalty income and funding from grants of research and development efforts. For the year ended December 31, 2021, other revenue also included cost reimbursements under a charitable support agreement which ended in June 2021. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Research and development grant revenue is recognized pursuant to International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance ("IAS 20") . The expenses are recorded in research and development expense and the reimbursements are recorded in other revenue. Funding of research and development efforts and charitable support reimbursements are recorded as the activities are performed in accordance with the respective agreements.
Deferred Revenue	Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2022 and 2021 included customer prepayments of $ 1,533 and $ 1,843 , respectively. Deferred revenue as of December 31, 2022 and 2021 also included $ 740 and $ 1,093 , respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of contract was determined based on expected revenues and revenue is recognized at that rate when the product is delivered to the customer.
Financing and Payment	Financing and Payment . The Company's payment terms vary by the type and location of our customer and products or services offered. Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer.
Practical Expedients and Exemptions	Practical expedients and exemptions . Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, the Company defers the cost of the commission and expenses it over the life of the related sales contract.
Revenues by Product	Revenues by product . The following table represents total net revenues by product line: Years ended December 31, 2022 2021 2020 COVID-19 $ 243,325 $ 76,874 $ 50,927 Genomics 54,335 63,350 36,878 HIV 38,812 42,144 44,224 HCV 13,369 11,783 8,448 Risk assessment testing 10,269 9,678 9,194 Microbiome 7,503 7,944 5,474 Laboratory services 7,296 11,840 8,746 Other product and service revenues 3,138 3,284 2,490 Net product and services revenues $ 378,047 $ 226,897 $ 166,381 Royalty income 2,683 4,420 3,432 Other non-product revenues 6,749 2,357 1,908 Other revenues 9,432 6,777 5,340 Net revenues $ 387,479 $ 233,674 $ 171,721
Revenues by Geographic Area	Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Years ended December 31, 2022 2021 2020 United States $ 350,206 $ 188,383 $ 130,835 Europe 11,536 13,799 12,068 Other regions 25,737 31,492 28,818 $ 387,479 $ 233,674 $ 171,721
Customer and Vendor Concentrations	Customer and Vendor Concentrations. The Company had one customer that accounted for more than 57 % of the Company's consolidated accounts receivable as of December 31, 2022 and no ne as of December 31, 2021. The same customer accounted for approximately 58 % of the Company's consolidated revenues for the year ended December 31, 2022. The Company had no customers that accounted for more than 10% of the Company's consolidated net revenues for the years ended December 31, 2021 and 2020. The Company currently purchases certain products and critical components of the Company's products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of the Company's products to the Company's customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on the Company's business, as well as the Company's financial condition and results of operations. The Company’s Intercept i2 ® he collection device is manufactured and supplied under a long-term agreement with Thermo Fisher, the sole-source supplier for these products. DNAG has three long-term contract manufacturing relationships to supply virtually all of its products, including the Oragene ® product line. Many of the raw materials and components used in these products are also purchased from third parties, some of which are purchased from a single source supplier. The Company is actively seeking to qualify other suppliers that can manufacture and supply the raw materials and components for the DNAG products.
Business Combinations and Contingent Consideration	Business Combinations and Contingent Consideration Acquired businesses are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to contingent consideration are recorded to the balance sheet at the date of acquisition based on their relative fair values. The purchase price allocation requires the Company to make significant estimates and assumptions, especially at the acquisition date, with respect to intangible assets. Although the Company believes the assumptions and estimates it has made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired companies and are inherently uncertain. The Company accounts for contingent consideration in accordance with applicable guidance provided within the business combination accounting standard. As part of the Company's consideration for the recent acquisitions, the Company is contractually obligated to pay certain consideration resulting from the outcome of future events. Therefore, the Company is required to update the Company's underlying assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in the Company's consolidated statements of operations. The Company's estimates of fair value are based on assumptions the Company believes to be reasonable, but the assumptions are uncertain and involve significant judgment by management. Updates to these assumptions could have a significant impact on the Company's results of operations in any given period and any updates to the fair value of the contingent consideration could differ materially from the previous estimates. Examples of critical estimates used in valuing certain intangible assets and contingent consideration include: • future expected cash flows from sales and acquired developed technologies; • the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio; • the probability of meeting the future events; and • discount rates used to determine the present value of estimated future cash flows. These estimates are inherently uncertain and unpredictable, and if different estimates were used the purchase price for the acquisition could be allocated to the acquired assets and liabilities differently from the allocation that the Company has made. In addition, unanticipated events and circumstances may occur, which may affect the accuracy or validity of such estimates, and if such events occur the Company may be required to record a charge against the value ascribed to an acquired asset or an increase in the amounts recorded for assumed liabilities .
Research and Development	Research and Development Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.
Advertising Expenses	Advertising Expenses Advertising costs are charged to expense as incurred. During 2022, 2021, and 2020, the Company incurred $ 4,849 , $ 5,103 , and $ 1,126 , respectively, in advertising expenses.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation to employees and directors using the fair value method. The Company recognizes compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. The Company recognizes compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, the Company issues new shares rather than purchase shares in the open market.
Income Taxes	Income Taxes The Company follows the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company assesses the realizability of the Company's net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, the Company reduces its net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the Company's net operating loss carryforwards.
Foreign Currency Translation	Foreign Currency Translation The assets and liabilities of the Company's foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in the Company's consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in the Company's consolidated statements of operations were $ 1,553 , $( 667 ) , and $( 337 ) for the years ended December 31, 2022, 2021, and 2020 , respectively.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is anti-dilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive. For the years ended December 31, 2022, 2021, and 2020 outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 436 , 769 , and 984 shares, respectively, were excluded from the computation of diluted loss per share.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The Company classifies items of other comprehensive income (loss) by their nature and discloses the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of the Company's consolidated balance sheets. The Company has defined the Canadian dollar as the functional currency of the Company's Canadian subsidiary, DNAG, and the Company has defined the Euro as the functional currency of the Company's Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2022 consists of $ 18,215 of currency translation adjustments and $ 220 of net unrealized losses on marketable securities. Accumulated other comprehensive loss at December 31, 2021 consists of $ 9,643 of currency translation adjustments and $ 434 of net unrealized losses on marketable securities, which represents the fair market value adjustment for the Company's investments portfolio.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU were effective upon issuance and could be applied prospectively through December 31, 2022. The FASB issued an amendment, ASU 2022-06, Deferral of the Sunset Date of Topic 848, in December 2022, which, extends the date for prospective application to December 31, 2024. Management has evaluated this ASU and concluded that it will not have a material impact on the Company's Consolidated Financial Statements .
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to current year presentation. See Note 4 for discussion of the reclassification related to the U.S. Department of Defense contract.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Available-for-sale Securities	The following is a summary of the Company's available-for-sale securities as of December 31, 2022 and 2021: Amortized Gross Gross Fair Value December 31, 2022 Guaranteed investment certificates $ 22,109 $ — $ — $ 22,109 Corporate bonds 4,978 — ( 220 ) 4,758 Total available-for-sale securities $ 27,087 $ — $ ( 220 ) $ 26,867 December 31, 2021 Guaranteed investment certificates $ 33,249 $ — $ — $ 33,249 Corporate bonds 20,473 — ( 434 ) 20,039 Total available-for-sale securities $ 53,722 $ — $ ( 434 ) $ 53,288 At December 31, 2022, maturities of the Company's available-for-sale securities were as follows: Less than one year $ 27,087 $ — $ ( 220 ) $ 26,867 Greater than one year $ — $ — $ — $ —
Disaggregation of Revenue by Product and Geographic Area	Revenues by product . The following table represents total net revenues by product line: Years ended December 31, 2022 2021 2020 COVID-19 $ 243,325 $ 76,874 $ 50,927 Genomics 54,335 63,350 36,878 HIV 38,812 42,144 44,224 HCV 13,369 11,783 8,448 Risk assessment testing 10,269 9,678 9,194 Microbiome 7,503 7,944 5,474 Laboratory services 7,296 11,840 8,746 Other product and service revenues 3,138 3,284 2,490 Net product and services revenues $ 378,047 $ 226,897 $ 166,381 Royalty income 2,683 4,420 3,432 Other non-product revenues 6,749 2,357 1,908 Other revenues 9,432 6,777 5,340 Net revenues $ 387,479 $ 233,674 $ 171,721 Revenues by geographic area . The following table represents total net revenues by geographic area, based on the location of the customer: Years ended December 31, 2022 2021 2020 United States $ 350,206 $ 188,383 $ 130,835 Europe 11,536 13,799 12,068 Other regions 25,737 31,492 28,818 $ 387,479 $ 233,674 $ 171,721

Business Combinations (Tables)

Business Combinations (Tables) - UrSure Inc [Member]	12 Months Ended
	Dec. 31, 2022
Summary of Change in Contingent Consideration	The following table represents the change in contingent consideration: Estimated fair value of contingent consideration as of acquisition date $ 3,440 Change in fair value during the period ( 989 ) Balance as of December 31, 2020 2,451 Payments made during the period ( 406 ) Change in fair value during the period ( 1,485 ) Balance as of December 31, 2021 560 Payments made during the period ( 208 ) Change in fair value during the period ( 188 ) Balance as of December 31, 2022 $ 164
Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed	Assets Acquired Accounts receivable $ 285 Other current assets 24 Other assets 6 Intangibles 3,600 Goodwill 3,586 Total assets acquired 7,501 Liabilities Assumed Current liabilities 335 Deferred tax liability 689 Total liabilities assumed 1,024 Net Assets Acquired 6,477 Fair value of contingent consideration ( 3,440 ) Net Cash Paid (net of cash acquired of $ 111 ) $ 3,037

Government Capital Contracts (T

Government Capital Contracts (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Government Contracts Balance Included in Consolidated Balance Sheet	The balances corresponding to government contracts included in the Company's consolidated balance sheet are as follows: December 31, December 31, Other current assets: Billed receivables $ — $ 9,913 Unbilled receivables 27,013 20,591 Total other current assets 27,013 30,504 Other non-current assets — 3,854 Accrued expenses and other current liabilities $ ( 318 ) $ ( 8,103 )
Summary of Government Contracts Balances Included In Consolidated Statements Of Cashflows	The activity corresponding to the government contracts included in the Company's consolidated statements of cashflows is as follows: December 31, December 31, Cost of assets, cumulative $ 83,359 $ 26,224 Reduction for funding earned to date, not yet received ( 22,497 ) ( 25,693 ) Reduction for funding received to date ( 60,862 ) ( 531 ) Total property, plant and equipment, net $ — $ —

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	December 31, 2022 2021 Raw materials $ 42,445 $ 33,168 Work in process 2,335 2,252 Finished goods 51,452 17,718 $ 96,232 $ 53,138

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	December 31, 2022 2021 Land $ 1,118 $ 1,118 Buildings and improvements 35,582 35,420 Machinery and equipment 60,725 57,919 Computer equipment and software 16,681 14,700 Furniture and fixtures 4,064 4,228 Construction in progress 11,124 21,207 129,294 134,592 Less accumulated depreciation ( 69,881 ) ( 61,157 ) $ 59,413 $ 73,435

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table represents total goodwill by operating segment: December 31, 2022 2021 Diagnostics $ — $ 3,604 Molecular Solutions 35,104 36,675 $ 35,104 $ 40,279 The changes in goodwill are as follows: December 31, 2022 2021 Balance as of January 1 $ 40,279 $ 40,351 Impairment ( 3,604 ) — Purchase price adjustment — 18 Change related to foreign currency translation ( 1,571 ) ( 90 ) Balance as of December 31 $ 35,104 $ 40,279
Summary of Intangible Assets	Intangible assets consist of the following: December 31, 2022 Amortization Gross Accumulated Amortization Net Customer relationships 10 $ 14,286 $ ( 11,011 ) $ 3,275 Patents and product rights 5 7,620 ( 6,615 ) 1,005 Developed technology 7 - 10 15,478 ( 9,940 ) 5,538 Tradename 5 - 15 5,387 ( 3,511 ) 1,876 $ 42,771 $ ( 31,077 ) $ 11,694 December 31, 2021 Amortization Gross Accumulated Net Customer relationships 10 $ 15,016 $ ( 11,205 ) $ 3,811 Patents and product rights 5 7,785 ( 6,241 ) 1,544 Developed technology 7 - 10 16,293 ( 9,725 ) 6,568 Tradename 5 - 15 5,661 ( 3,241 ) 2,420 $ 44,755 $ ( 30,412 ) $ 14,343
Summary of Amortization Expense	Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows: 2023 $ 2,221 2024 2,183 2025 1,947 2026 1,591 2027 1,520 Beyond 2,232 $ 11,694

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	December 31, 2022 2021 Payroll and related benefits $ 14,103 $ 15,570 Commitment to purchase under government contract — 8,103 Professional fees 4,685 3,335 Sales tax payable 1,519 2,227 Other 5,455 4,543 $ 25,762 $ 33,778

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Summary of Components of Lease Expense	The components of lease expense are as follows: Years ended December 31, 2022 2021 2020 Operating lease cost $ 2,910 $ 2,226 $ 1,291 Variable and short-term lease cost 521 201 — Finance lease cost: Amortization of right-of use assets 1,299 900 627 Interest on lease liabilities 94 82 72 Total finance lease cost 1,393 982 699 Total lease cost $ 4,824 $ 3,409 $ 1,990
Summary of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases is as follows: Years ended December 31, 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,209 $ 3,733 $ 1,280 Operating cash flows from financing leases 94 82 72 Financing cash flows from financing leases 1,381 686 687 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations 3,963 6,480 498 Right-of-use assets obtained in exchange for finance lease obligations 117 2,074 46
Summary of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows: December 31, 2022 2021 Operating Leases Right-of-use assets $ 10,399 $ 9,056 Lease liabilities: Current lease liabilities 1,764 2,181 Non-current lease liabilities 9,101 7,202 Total operating lease liabilities $ 10,865 $ 9,383 Finance Leases Right-of-use assets $ 1,293 $ 2,493 Lease liabilities: Current lease liabilities 1,179 939 Non-current lease liabilities 503 1,952 Total finance lease liabilities $ 1,682 $ 2,891
Summary of Lease Term and Discount Rate	Weighted Average Remaining Lease Term Weighted-average remaining lease term—operating leases 6.24 years 5.26 years Weighted-average remaining lease term—finance leases 1.33 years 2.21 years Weighted Average Discount Rate Weighted-average discount rate—operating leases 4.06 % 3.90 % Weighted-average discount rate—finance leases 3.44 % 3.57 %
Schedule of Minimum Lease Payments by Period Expected	As of December 31, 2022, minimum lease payments by period are expected to be as follows: Finance Operating 2023 $ 1,216 $ 1,898 2024 505 2,311 2025 20 1,928 2026 12 1,710 2027 — 1,544 Thereafter — 3,083 Total minimum lease payments 1,753 12,474 Less: imputed interest ( 71 ) ( 1,609 ) Present value of lease liabilities $ 1,682 $ 10,865

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Income Tax Expense (Benefit)	Income (loss) before income tax expense consists of the following: Years Ended December 31, 2022 2021 2020 United States $ ( 7,912 ) $ ( 60,500 ) $ ( 47,995 ) Foreign ( 8,564 ) 51,208 44,471 $ ( 16,476 ) $ ( 9,292 ) $ ( 3,524 )
Components of Income Tax Expense (Benefit)	The components of income tax expense (benefit) are as follows: Years Ended December 31, 2022 2021 2020 Current Federal $ — $ — $ — State 955 163 ( 106 ) Foreign 2,154 12,517 11,896 3,109 12,680 11,790 Deferred Federal ( 2,250 ) ( 10,318 ) ( 20,946 ) State ( 633 ) ( 965 ) ( 1,053 ) Foreign ( 2,617 ) ( 151 ) ( 410 ) ( 5,500 ) ( 11,434 ) ( 22,409 ) Increase (decrease) in valuation allowance 3,849 12,460 22,017 ( 1,651 ) 1,026 ( 392 ) Total income tax expense $ 1,458 $ 13,706 $ 11,398
Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate	A reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate for each of the years ended December 31, 2022, 2021, and 2020 is as follows: 2022 2021 2020 Statutory U.S. federal income tax rate 21.0 % 21.0 % 21.0 % Nondeductible executive compensation ( 5.5 ) ( 6.1 ) ( 0.9 ) Impact of share-based payment awards ( 4.8 ) ( 3.3 ) ( 12.4 ) Tax effect of foreign items ( 5.7 ) ( 30.8 ) ( 70.7 ) State income taxes, net of federal benefit ( 0.8 ) 6.8 26.0 U.S. and foreign tax credits 3.6 2.5 34.9 Nondeductible transaction costs — — ( 2.8 ) Nondeductible expenses and other 7.0 ( 4.0 ) ( 2.6 ) NOL adjustment due to change in GILTI regulations — — 308.9 Change in valuation allowance, federal and state ( 23.7 ) ( 133.6 ) ( 624.8 ) Effective tax rate ( 8.9 ) % ( 147.5 ) % ( 323.4 ) %
Components of Total Deferred Tax Assets (Liabilities)	Significant components of the Company's deferred tax assets (liabilities) as of December 31, 2022 and 2021 are as follows: 2022 2021 Deferred tax assets (liabilities): Net operating loss carryforwards $ 39,783 $ 44,191 Inventories 4,504 4,642 Capitalized research and development costs 6,505 453 Accruals and reserves currently not deductible 2,799 3,245 Acquired intangible assets ( 2,641 ) ( 3,117 ) Depreciation and amortization ( 6,227 ) ( 8,536 ) Right-of-use assets ( 2,775 ) ( 2,777 ) Lease liabilities 2,990 2,957 Stock-based compensation 3,032 1,891 Tax credit carryforwards 4,509 3,855 Net deferred tax asset 52,479 46,804 Valuation allowance ( 52,887 ) ( 49,038 ) Net deferred tax liability $ ( 408 ) $ ( 2,234 )
Expiry Details of Federal Net Operating Losses Carryforwards	Federal NOL carryforwards expire as follows: Year of Expiration NOLs 2030 - 2033 $ 36,107 2034 - 2037 12,055 Non-Expiring 117,885 $ 166,047
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of the Company's unrecognized tax benefits is as follows: 2022 2021 2020 Balance as of January 1 $ 805 $ 1,172 $ 1,308 Additions for tax positions of prior periods 1 1 1 Reductions for tax positions of prior periods ( 433 ) ( 368 ) ( 137 ) Balance as of December 31 $ 373 $ 805 $ 1,172

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Weighted-Average Assumptions for Fair Value Measurement	The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions: Years Ended December 31, Black-Scholes Option Valuation Assumptions 2022 2021 2020 Risk-free interest rate (1) 1.65 % 0.47 % 1.33 % Expected dividend yield — — — Expected stock price volatility (2) 50 % 50 % 42 % Expected life of stock options (in years) (2) 5 5 5 (1) Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options. (2) Based upon historical experience.
Summary of Company's Stock Option Activity	The following table summarizes the stock option activity under the Stock Plan: Options Weighted- Weighted- Aggregate Intrinsic Value Outstanding on January 1, 2022 1,410 $ 10.73 Granted 589 8.86 Exercised ( 2 ) 7.17 Expired ( 28 ) 10.01 Forfeited ( 211 ) 9.63 Outstanding on December 31, 2022 1,758 $ 10.25 6.54 $ — Vested or expected to vest as of December 31, 2022 1,633 $ 10.29 7.03 $ — Exercisable on December 31, 2022 1,045 $ 10.67 5.11 $ —
Schedule of Currently Outstanding and Exercisable Stock Options	The following table summarizes information about stock options outstanding as of December 31, 2022: Options outstanding Options exercisable Range of exercise prices Number Weighted- Weighted- Number Weighted- $ 5.37 -$ 8.86 1,036 7.2 $ 7.83 435 $ 6.83 $ 8.87 -$ 13.31 362 4.8 10.67 357 10.64 $ 14.95 -$ 22.43 360 6.5 16.79 253 17.30 1,758 6.5 $ 10.25 1,045 $ 10.67
Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan	The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan: Units Weighted- Issued and unvested, January 1, 2022 701 $ 11.53 Granted 2,995 6.45 Vested ( 750 ) 9.50 Forfeited ( 373 ) 9.47 Issued and unvested, December 31, 2022 2,573 $ 6.51 Issued and expected to vest, December 31, 2022 2,538 $ 6.53
Performance Based Restricted Stock Unit [Member]
Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan	The following table summarizes PSU activity under the Stock Plan: Units Weighted- Issued and unvested, January 1, 2022 622 $ 9.88 Granted (1) 532 8.86 Performance adjustment (2) 36 N/A Vested ( 241 ) 11.09 Forfeited ( 234 ) 10.50 Issued and unvested, December 31, 2022 715 $ 6.86 Issued and expected to vest, December 31, 2022 698 $ 6.82 (1) Grant activity for all PSUs disclosed at target. (2) Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Summary of Operating Segment and Asset Information	The following table summarizes operating segment information for the years ended December 31, 2022, 2021, and 2020, and asset information as of December 31, 2022 and 2021: Years ended December 31, 2022 2021 2020 Net revenues: Diagnostics $ 303,673 $ 90,040 $ 65,240 Molecular Solutions 83,806 143,634 106,481 Total $ 387,479 $ 233,674 $ 171,721 Operating income (loss): Diagnostics $ ( 598 ) $ ( 57,177 ) $ ( 43,156 ) Molecular Solutions ( 22,359 ) 47,013 37,979 Total $ ( 22,957 ) $ ( 10,164 ) $ ( 5,177 ) Depreciation and amortization: Diagnostics $ 8,099 $ 4,325 $ 3,345 Molecular Solutions 7,209 7,333 6,042 Total $ 15,308 $ 11,658 $ 9,387 Capital expenditures: Diagnostics (1) $ 3,644 $ 12,265 $ 17,860 Molecular Solutions 3,130 9,628 8,814 Total $ 6,774 $ 21,893 $ 26,674 (1) Excludes $ 57,135 and $ 26,224 for purchases of property and equipment under government contracts for the years ended December 31, 2022 and 2021 respectively. No purchases of property and equipment under government contracts were made in 2020. December 31, 2022 2021 Total assets: Diagnostics $ 279,994 $ 209,674 Molecular Solutions 164,714 251,316 Total $ 444,708 $ 460,990
Presentation of Total Long-Lived Assets by Geographic Area	The following table represents total long-lived assets by geographic area: December 31, 2022 2021 United States $ 60,751 $ 72,376 Canada 8,526 11,488 Other regions 1,828 1,120 $ 71,105 $ 84,984

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Estimate of Future Purchases	The table below represents an estimate of future purchases under those agreements. 2023 $ 21,710 2024 9,695 2025 6,928 2026 — 2027 — $ 38,333

The Company - Additional Inform

The Company - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid	$ 9,446	$ 13,727	$ 9,263
Write-offs against allowance for doubtful accounts	2,296	115	501
Accruals for purchases of property and equipment	227	8,166	802
Cash and cash equivalents	83,980	116,762
Fair value of plan assets	747	1,763
Deferred revenue	$ 2,273	2,936
Contract with customer payment terms, description	Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.
Advertising expenses	$ 4,849	5,103	1,126
Net foreign exchange (losses) gains	1,553	(667)	$ (337)
Accumulated foreign currency adjustments included in other comprehensive loss amounted	18,215	9,643
Unrealized loss on marketable securities	220	434
Long-term Contract [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	740	1,093
Money Market Fund [Member] | Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 1,730	$ 1,160
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation	436	769	984
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 1,533	$ 1,843
Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	57%	0%
Customer [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	58%
Cost of Products and Service Sold [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		$ 2,536
Research and Development [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		1,134
Sales and Marketing [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		924
General and Administrative Costs [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee retention credit		1,134
Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Contract with customer payment terms	30 days
Minimum [Member] | Computer Equipment and Software [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Contract with customer payment terms	120 days
Sales commissions amortization period	1 year
Maximum [Member] | Computer Equipment and Software [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Internal Revenue Service (IRS) [Member] | Other Current Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amount due from Internal Revenue Services	$ 5,728	$ 5,728

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 27,087	$ 53,722
Gross Unrealized Losses	(220)	(434)
Fair Value	26,867	53,288
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	22,109	33,249
Fair Value	22,109	33,249
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	4,978	20,473
Gross Unrealized Losses	(220)	(434)
Fair Value	4,758	$ 20,039
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	27,087
Gross Unrealized Losses	(220)
Fair Value	$ 26,867

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenues	$ 387,479	$ 233,674	$ 171,721
Product and Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	378,047	226,897	166,381
Product and Services Revenues [Member] | COVID-19 [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	243,325	76,874	50,927
Product and Services Revenues [Member] | Genomics [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	54,335	63,350	36,878
Product and Services Revenues [Member] | HIV [ Member ]
Disaggregation Of Revenue [Line Items]
Net revenues	38,812	42,144	44,224
Product and Services Revenues [Member] | HCV [ Member ]
Disaggregation Of Revenue [Line Items]
Net revenues	13,369	11,783	8,448
Product and Services Revenues [Member] | Risk Assessment Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	10,269	9,678	9,194
Product and Services Revenues [Member] | Microbiome [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	7,503	7,944	5,474
Product and Services Revenues [Member] | Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	7,296	11,840	8,746
Product and Services Revenues [Member] | Other Product And Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	3,138	3,284	2,490
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	9,432	6,777	5,340
Other [Member] | Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,683	4,420	3,432
Other [Member] | Other Non Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 6,749	$ 2,357	$ 1,908

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenues	$ 387,479	$ 233,674	$ 171,721
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	350,206	188,383	130,835
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,536	13,799	12,068
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 25,737	$ 31,492	$ 28,818

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Jul. 22, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current		$ 99	$ 354
Net revenues		387,479	233,674	$ 171,721
Net income (loss)		$ (17,934)	$ (22,998)	(14,922)
UrSure Inc [Member]
Business Acquisition [Line Items]
Purchase price	$ 3,000
Business acquisition contingent consideration, non-current	$ 28,000
Business combination contingent consideration expected payment period	3 years
Estimated fair value of contingent consideration	$ 3,440
Acquisition-related costs				$ 393
Total consideration	$ 3,037
UrSure Inc [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)	10 years

Business Combinations - Summary

Business Combinations - Summary of Change in Contingent Consideration (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition, Contingent Consideration [Line Items]
Change in fair value during the period	$ (188)	$ (1,485)	$ (1,099)
Ur Sure Inc [Member]
Business Acquisition, Contingent Consideration [Line Items]
Beginning Balance	560	2,451
Estimated fair value of contingent consideration as of acquisition date			3,440
Payments made during the period	(208)	(406)
Change in fair value during the period	(188)	(1,485)	(989)
Ending Balance	$ 164	$ 560	$ 2,451

Business Combinations - Summa_2

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 22, 2020
Assets Acquired
Goodwill	$ 35,104	$ 40,279	$ 40,351
UrSure Inc [Member]
Assets Acquired
Accounts receivable				$ 285
Other current assets				24
Other assets				6
Intangibles				3,600
Goodwill				3,586
Total assets acquired				7,501
Liabilities Assumed
Current liabilities				335
Deferred tax liability				689
Total liabilities assumed				1,024
Net Assets Acquired				6,477
Fair value of contingent consideration				(3,440)
Net Cash Paid				$ 3,037

Business Combinations - Summa_3

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands		12 Months Ended
	Jul. 22, 2020	Dec. 31, 2020
Business Acquisition [Line Items]
Net of cash acquired		$ 3,037
UrSure Inc [Member]
Business Acquisition [Line Items]
Net of cash acquired	$ 111

Government Capital Contracts -

Government Capital Contracts - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Government capital contracts funding amount					$ 109,000
Property, plant and equipment, net		$ 59,413	$ 73,435
Proceeds from funding under government contract	$ 60,331,000	60,331	531
Remaining expected Fund Under Government Contract		$ 48,669,000
Percentage withheld under government contracts subject to validation testing		15%
Net revenues		$ 387,479	233,674	$ 171,721
Government Contract [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Property, plant and equipment, net		0	0
Reduction in property, plant and equipment			(14,729)
Increase in other current assets			10,875
Increase in other noncurrent assets			3,854
Revision of Prior Period, Reclassification, Adjustment [Member] | Government Contract [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Property, plant and equipment, net			14,729
Other Income [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues		9,432	6,777	$ 5,340
Other Income [Member] | Government Contract [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues		2,246	$ 561
Research and Development Expenses and Other Income [Member] | Government Contract [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursement of engineering cost		$ 1,422

Government Capital Contracts _2

Government Capital Contracts - Summary of Government Contracts Balance Included in Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other current assets:
Total other current assets	$ 41,569	$ 39,865
Other noncurrent assets	1,087	5,069
Accrued expenses and other current liabilities	25,762	33,778
Government Contract [Member]
Other current assets:
Billed receivables	0	9,913
Unbilled receivables	27,013	20,591
Total other current assets	27,013	30,504
Other noncurrent assets	0	3,854
Accrued expenses and other current liabilities	$ (318)	$ (8,103)

Government Capital Contracts _3

Government Capital Contracts - Summary of Government Contracts Included in Statements of Cashflows (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative	$ 129,294	$ 134,592
Property plant and equipment Net	59,413	73,435
Government Contract [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative	83,359	26,224
Reduction for funding earned, not yet received	(22,497)	(25,693)
Reduction for funding received	(60,862)	(531)
Property plant and equipment Net	$ 0	$ 0

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory, Net [Abstract]
Raw materials	$ 42,445	$ 33,168
Work in process	2,335	2,252
Finished goods	51,452	17,718
Inventories	$ 96,232	$ 53,138

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Inventory [Line Items]
Inventory adjustments	$ 15,618	$ 13,400	$ 2,564
COVID-19 Antibody
Inventory [Line Items]
Inventory adjustments		$ 3,008

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 129,294	$ 134,592
Less accumulated depreciation	(69,881)	(61,157)
Property plant and equipment Net	59,413	73,435
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	35,582	35,420
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	60,725	57,919
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	16,681	14,700
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	4,064	4,228
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 11,124	$ 21,207

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 11,740	$ 7,498	$ 5,514
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]	Asset Impairment Charges
Molecular Solutions [Member]
Property, Plant and Equipment [Line Items]
Pre-tax asset impairment charge	$ 8,585
Diagnostics [Member]
Property, Plant and Equipment [Line Items]
Pre-tax asset impairment charge	$ 4,912

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill by Operating Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Goodwill	$ 35,104	$ 40,279	$ 40,351
Diagnostics [Member]
Goodwill [Line Items]
Goodwill		3,604
Molecular Solutions [Member]
Goodwill [Line Items]
Goodwill	$ 35,104	$ 36,675

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Beginning Balance	$ 40,279	$ 40,351
Impairment	(3,604)
Purchase price adjustment		18
Change related to foreign currency translation	(1,571)	(90)
Ending Balance	$ 35,104	$ 40,279

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 42,771	$ 44,755
Intangible Assets, Accumulated Amortization	(31,077)	(30,412)
Intangible Assets, Net	$ 11,694	$ 14,343
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 14,286	$ 15,016
Intangible Assets, Accumulated Amortization	(11,011)	(11,205)
Intangible Assets, Net	$ 3,275	$ 3,811
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years	5 years
Intangible Assets, Gross	$ 7,620	$ 7,785
Intangible Assets, Accumulated Amortization	(6,615)	(6,241)
Intangible Assets, Net	1,005	1,544
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	15,478	16,293
Intangible Assets, Accumulated Amortization	(9,940)	(9,725)
Intangible Assets, Net	$ 5,538	$ 6,568
Developed Technology [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Developed Technology [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 5,387	$ 5,661
Intangible Assets, Accumulated Amortization	(3,511)	(3,241)
Intangible Assets, Net	$ 1,876	$ 2,420
Tradename [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	5 years	5 years
Tradename [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Amortization expense	$ 2,269	$ 3,260	$ 3,246
Pre-tax impairment charge	$ 3,604

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022	$ 2,221
2023	2,183
2024	1,947
2025	1,591
2026	1,520
Beyond	2,232
Intangible Assets, Net	$ 11,694	$ 14,343

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 14,103	$ 15,570
Commitment to purchase under government contract	0	8,103
Professional fees	4,685	3,335
Sales tax payable	1,519	2,227
Other	5,455	4,543
Accrued expenses and other current liabilities	$ 25,762	$ 33,778

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Aggregate ROU asset and offsetting lease liability	$ 117	$ 2,074	$ 46
Fixed rent payments to be paid over lease term	$ 12,474
Leases in Purchase Commitment [Member]
Lessee Lease Description [Line Items]
Aggregate ROU asset and offsetting lease liability		$ 2,074
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	10 years

Leases - Summary of Components

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Operating lease cost	$ 2,910	$ 2,226	$ 1,291
Variable and short-term lease cost	521	201
Finance Lease Cost
Amortization of right-of use assets	1,299	900	627
Interest on lease liabilities	94	82	72
Total finance lease cost	1,393	982	699
Total lease cost	$ 4,824	$ 3,409	$ 1,990

Leases - Summary of Supplementa

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 2,209	$ 3,733	$ 1,280
Operating cash flows from financing leases	94	82	72
Financing cash flows from financing leases	1,381	686	687
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations	3,963	6,480	498
Right-of-use assets obtained in exchange for finance lease obligations	$ 117	$ 2,074	$ 46

Leases - Summary of Supplemen_2

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating Leases
Right-of-use assets	$ 10,399	$ 9,056
Lease liabilities:
Current lease liabilities	1,764	2,181
Non-current lease liabilities	9,101	7,202
Total operating lease liabilities	10,865	9,383
Finance Leases
Right-of-use assets	1,293	2,493
Lease liabilities:
Current lease liabilities	1,179	939
Non-current lease liabilities	503	1,952
Total finance lease liabilities	$ 1,682	$ 2,891

Leases - Summary of Lease Term

Leases - Summary of Lease Term and Discount Rate (Detail)	Dec. 31, 2022	Dec. 31, 2021
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	6 years 2 months 26 days	5 years 3 months 3 days
Weighted-average remaining lease term—finance leases	1 year 3 months 29 days	2 years 2 months 15 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.06%	3.90%
Weighted-average discount rate—finance leases	3.44%	3.57%

Leases - Schedule of Minimum Le

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finance Lease Liabilities, Payments, Due [Abstract]
2023	$ 1,216
2024	505
2025	20
2026	12
Total minimum finance lease payments	1,753
Less: imputed interest	(71)
Present Value of Finance Lease Liabilities	1,682	$ 2,891
Operating Lease Liabilities, Payments Due [Abstract]
2023	1,898
2024	2,311
2025	1,928
2026	1,710
2027	1,544
Thereafter	3,083
Total Minimum Operating Lease Payments	12,474
Less: imputed interest	(1,609)
Present Value of Operating Lease Liabilities	$ 10,865	$ 9,383

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]
United States	$ (7,912)	$ (60,500)	$ (47,995)
Foreign	(8,564)	51,208	44,471
Loss before income taxes	$ (16,476)	$ (9,292)	$ (3,524)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current
Federal	$ 0	$ 0	$ 0
State	955,000	163,000	(106,000)
Foreign	2,154,000	12,517,000	11,896,000
Total current income tax expense (benefit)	3,109,000	12,680,000	11,790,000
Deferred
Federal	(2,250,000)	(10,318,000)	(20,946,000)
State	(633,000)	(965,000)	(1,053,000)
Foreign	(2,617,000)	(151,000)	(410,000)
Total deferred income tax expense (benefit)	(5,500,000)	(11,434,000)	(22,409,000)
Increase (decrease) in valuation allowance	3,849,000	12,460,000	22,017,000
Deferred income taxes	(1,651,000)	1,026,000	(392,000)
Total income tax expense	$ 1,458,000	$ 13,706,000	$ 11,398,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2022	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Foreign income tax expense (benefit)		$ (1,200,000)	$ 503,000	$ 13,543,000	$ 12,185,000
U.S. federal income tax benefits			0	0	0
Foreign earnings repatriated	$ 65,000,000
Gross unrecognized tax benefits			373,000	805,000	1,172,000	$ 1,308,000
State income tax expense (benefit)		$ 955,000		163,000	(794,000)
Canada [Member]
Income Tax Contingency [Line Items]
Foreign income tax expense (benefit)				$ 13,543,000	$ 12,192,000
Withholding tax paid on the repatriation	$ 1,700,000		$ 1,703,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	21%	21%	21%
Nondeductible executive compensation	(5.50%)	(6.10%)	(0.90%)
Impact of share-based payment awards	(4.80%)	(3.30%)	(12.40%)
Tax effect of foreign items	(5.70%)	(30.80%)	(70.70%)
State income taxes, net of federal benefit	(0.80%)	6.80%	26%
U.S. and foreign tax credits	3.60%	2.50%	34.90%
Nondeductible transaction costs			(2.80%)
Nondeductible expenses and other	7%	(4.00%)	(2.60%)
NOL adjustment due to change in GILTI regulations			308.90%
Change in valuation allowance, federal and state	(23.70%)	(133.60%)	(624.80%)
Effective tax rate	(8.90%)	(147.50%)	(323.40%)

Income Taxes - Components of To

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 39,783	$ 44,191
Inventories	4,504	4,642
Capitalized research and development costs	6,505	453
Accruals and reserves currently not deductible	2,799	3,245
Acquired intangible assets	(2,641)	(3,117)
Depreciation and amortization	(6,227)	(8,536)
Right-of-use assets	(2,775)	(2,777)
Lease liabilities	2,990	2,957
Stock-based compensation	3,032	1,891
Tax credit carryforwards	4,509	3,855
Net deferred tax asset	52,479	46,804
Valuation allowance	(52,887)	(49,038)
Net deferred tax liability	$ (408)	$ (2,234)

Income Taxes - Expiry Details o

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 166,047
2030 - 2033 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	36,107
2034- 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	12,055
Non-Expiring [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 117,885

Income Taxes - Reconciliation_2

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as of January 1	$ 805	$ 1,172	$ 1,308
Additions for tax positions of prior periods	1	1	1
Reductions for tax positions of prior periods	(433)	(368)	(137)
Balance as of December 31	$ 373	$ 805	$ 1,172

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)		12 Months Ended
	Jun. 01, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan		3,921,000
Amount share repurchase program of common shares					$ 25,000,000
Total cost of common stock purchased and retired		$ 2,254,000	$ 2,113,000	$ 2,088,000
Proceeds from exercise of stock options		15,000	246,000	3,222,000
Income tax benefit realized from stock option exercises during period		0	0	0
Total compensation cost		$ 11,622,000	$ 7,807,000	$ 7,139,000
Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200, Shares	8,000,000
Public offering price per share	$ 11
Net offering proceeds after deducting underwriting discount and commission and offering expenses	$ 95,000,000
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriters option exercisable period	30 days
Underwriters option to purchase additional shares	1,200,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		0	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price		75%
Granted exercise periods		10 years
Vesting period		4 years
Vesting of Options		Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Weighted-average grant date fair value of stock options granted		$ 4.15	$ 6.14	$ 2.79
Aggregate intrinsic value of options exercised		$ 4,000	$ 130,000	$ 3,117,000
Unrecognized compensation expense related to unvested option awards		$ 2,583,000
Expected weighted-average period for recognition of compensation expense related to unvested awards		2 years 7 months 6 days
Proceeds from exercise of stock options		$ 15,000	246,000	3,222,000
Total compensation cost		$ 1,515,000	1,063,000	892,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards		1 year 9 months 18 days
Total compensation cost		$ 9,169,000	$ 4,094,000	$ 4,094,000
Unrecognized compensation expense related to unvested restricted stock awards		$ 11,185,000
Vesting of restricted shares, withholding and exercise obligations		241,000	107,000	127,000
Restricted shares of common stock, aggregate values		$ 1,621,000	$ 1,417,000	$ 1,219,000
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		88,000	46,000	121,000
Total cost of common stock purchased and retired		$ 633,000	$ 696,000	$ 869,000
Expected weighted-average period for recognition of compensation expense related to unvested awards		1 year 7 months 6 days
Total compensation cost		$ 938,000	$ 2,650,000	$ 2,153,000
Unrecognized compensation expense related to unvested restricted stock awards		$ 316,000
Maximum [Member] | Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted		200%
Minimum [Member] | Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted		0%

Stockholders' Equity - Weighted

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	[1]	1.65%	0.47%	1.33%
Expected dividend yield		0%	0%	0%
Expected stock price volatility	[2]	50%	50%	42%
Expected life of stock options (in years)	[2]	5 years	5 years	5 years
[1] Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options. Based upon historical experience.

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance | shares	1,410
Options, Granted | shares	589
Options, Exercised | shares	(2)
Options, Expired | shares	(28)
Options, Forfeited | shares	(211)
Options, Outstanding, Ending Balance | shares	1,758
Options, Vested or expected to vest | shares	1,633
Options, Exercisable | shares	1,045
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance | $ / shares	$ 10.73
Weighted-Average Exercise Price Per Share, Granted | $ / shares	8.86
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	7.17
Weighted-Average Exercise Price Per Share, Expired | $ / shares	10.01
Weighted-Average Exercise Price Per Share, Forfeited | $ / shares	9.63
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance | $ / shares	10.25
Weighted-Average Exercise Price Per Share, Vested or expected to vest | $ / shares	10.29
Weighted-Average Exercise Price Per Share, Exercisable | $ / shares	$ 10.67
Weighted-Average Remaining Contractual Term, Outstanding	6 years 6 months 14 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	7 years 10 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 1 month 9 days

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding | shares	1,758
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.25
Number Exercisable, Options exercisable | shares	1,045
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.67
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.37
Range of exercise prices, Upper Range Limit	$ 8.86
Number Outstanding, Options outstanding | shares	1,036
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years 2 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.83
Number Exercisable, Options exercisable | shares	435
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.83
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	8.87
Range of exercise prices, Upper Range Limit	$ 13.31
Number Outstanding, Options outstanding | shares	362
Weighted-Average Remaining Contractual Term (in years), Options outstanding	4 years 9 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.67
Number Exercisable, Options exercisable | shares	357
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.64
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	14.95
Range of exercise prices, Upper Range Limit	$ 22.43
Number Outstanding, Options outstanding | shares	360
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 16.79
Number Exercisable, Options exercisable | shares	253
Weighted-Average Exercise Price Per Share, Options exercisable	$ 17.30

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance | shares	701
Shares, Granted | shares	2,995
Shares, Vested | shares	(750)
Shares, Forfeited | shares	(373)
Shares, Issued and unvested, Ending Balance | shares	2,573
Shares, Issued and expected to vest | shares	2,538
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance | $ / shares	$ 11.53
Weighted-Average Grant Date Fair Value, Granted | $ / shares	6.45
Weighted-Average Grant Date Fair Value, Vested | $ / shares	9.50
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	9.47
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance | $ / shares	6.51
Weighted-Average Grant Date Fair Value, Issued and expected to vest | $ / shares	$ 6.53

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	622
Shares, Granted	532	[1]
Performance adjustment	36	[2]
Shares, Vested	(241)
Shares, Forfeited	(234)
Shares, Issued and unvested, Ending Balance	715
Shares, Issued and expected to vest	698
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance | $ / shares	$ 9.88
Weighted-Average Grant Date Fair Value, Granted | $ / shares	8.86	[1]
Weighted-Average Grant Date Fair Value, Vested | $ / shares	11.09
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	10.50
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance | $ / shares	6.86
Weighted-Average Grant Date Fair Value, Issued and expected to vest | $ / shares	$ 6.82
[1] Grant activity for all PSUs disclosed at target. Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Transition Costs - Additional I

Transition Costs - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Transition Costs [Line Items]
Severance accrual		$ 1,569
Stock-based compensation	$ 11,622	$ 7,807	$ 7,139
Transition costs [Member]
Transition Costs [Line Items]
Stock-based compensation	$ 1,508

Business Segment Information -

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information _2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net revenues	$ 387,479	$ 233,674	$ 171,721
Operating income (loss)	(22,957)	(10,164)	(5,177)
Depreciation and amortization	15,308	11,658	9,387
Capital expenditures	6,774	21,893	26,674
Total assets	444,708	460,990
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	303,673	90,040	65,240
Operating income (loss)	(598)	(57,177)	(43,156)
Depreciation and amortization	8,099	4,325	3,345
Capital expenditures	3,644	12,265	17,860
Total assets	279,994	209,674
Molecular Solutions [Member]
Segment Reporting Information [Line Items]
Net revenues	83,806	143,634	106,481
Operating income (loss)	(22,359)	47,013	37,979
Depreciation and amortization	7,209	7,333	6,042
Capital expenditures	3,130	9,628	$ 8,814
Total assets	$ 164,714	$ 251,316

Business Segment Information _3

Business Segment Information - Summary of Operating Segment and Asset Information (Parenthetical) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Purchases of property and equipment under government contracts	$ 57,135,000	$ 26,224,000
Diagnostics [Member]
Segment Reporting Information [Line Items]
Purchases of property and equipment under government contracts	$ 57,135,000	$ 26,224,000	$ 0

Business Segment Information _4

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Long lived assets	$ 71,105	$ 84,984
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long lived assets	60,751	72,376
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long lived assets	8,526	11,488
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long lived assets	$ 1,828	$ 1,120

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Estimate of Future Purchases (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Purchase Obligation, Fiscal Year Maturity [Abstract]
2023	$ 21,710
2024	9,695
2025	6,928
Total	$ 38,333

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Purchase Obligation, Fiscal Year Maturity [Abstract]
Estimated penalties to be incurred under minimum purchase commitments	$ 1,143

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	1,763,000		$ 1,295,000	$ 994,000
Value of the assets associated with the plan	747,000		1,763,000
Total obligation under plan	747,000		1,763,000
RRSP [Member] | DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions		$ 4,000
Contributed to plan, net of forfeitures	$ 453,000		$ 448,000	$ 366,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Feb. 14, 2023
Subsequent Event [Member]
Subsequent Event [Line Items]
Reduction percentage on non-production workforce	11%